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 Adult cancers often arise due to the accumulation of mutations over time, while 
pediatric malignancies occur early in life and may result from disruption of normal 
developmental processes. Ewing sarcoma is an undifferentiated neoplasm and the second 
most common bone associated tumor in children and young adults. This is an aggressive 
disease and effective treatment for those with metastatic disease is lacking. The EWS/FLI 
translocation encodes an oncogenic transcription factor and the principle driver of the 
disease. This fusion protein relies on a very specific cellular context in order to 
dysregulate transcription of several thousand genes including many developmental 
regulators. The presence of the translocation in a permissive cell type may be sufficient to 
drive the transformation process. The specific oncogenic contributions made by 
EWS/FLI target genes and identification of the cell of origin – which remains unknown – 
will lead to targeted treatment options based on the molecular underpinnings of the 
disease. Toward this goal, we identified BCL11B as an up-regulated EWS/FLI target 
necessary for maintenance of transformation. Genome wide expression profiling of 
BCL11B regulated genes revealed that BCL11B is responsible for a significant portion of 
the EWS/FLI repressed gene signature. The normal function of BCL11B as a 
transcriptional repressor in many developmental processes, suggests that inappropriate 
expression of BCL11B in the incipient Ewing sarcoma cell leads to aberrant expression 
of genes involved in several cell lineages, thus contributing to the poorly differentiated 
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phenotype in Ewing sarcoma. Next we shifted our focus away from EWS/FLI target 
genes to identify genes present in the precursor cell that maintain Ewing sarcoma in an 
undifferentiated state and may foster a permissive cellular environment for EWS/FLI. 
ZEB2 expression is not dependent on EWS/FLI levels, but it is highly expressed in 
Ewing sarcoma tumors. ZEB2 represses epithelial gene expression in Ewing sarcoma 
cells. Reduction of ZEB2 allows for expression of epithelial genes and corresponding 
decreases in cell mobility and actin cytoskeleton rearrangements. Furthermore, the 
emergence of these epithelial phenotypes decreased the metastatic potential of Ewing 
sarcoma cells in a mouse metastasis model. This heretofore unrecognized epithelial 
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 Malignancies affecting the pediatric and young adult population have a unique 
biology when compared to those occurring in older individuals. Sarcomas, tumors that 
are thought to arise from mesenchymal tissues, are the most common solid tumor in this 
age group (Bleyer et al, 2008). A more complete understanding of the molecular 
mechanisms that contribute to cancer formation in this young population will inform 
better treatment strategies for this subset of patients. The work in this thesis will focus on 
a specific class of sarcoma, Ewing sarcoma. Ewing sarcoma is most commonly diagnosed 
in the second decade of life and is often bone-associated, but can also occur in soft tissue 
such as kidney and pancreas (Taylor et al, 2011). This highly aggressive neoplasm is 
characterized by the t(11;22)(q24;q12) chromosomal translocation resulting in the 
oncogenic transcription factor, EWS/FLI (Delattre et al, 1992; Turc-Carel et al, 1988). A 
detailed review of Ewing sarcoma is presented in Chapter 2.     
 In 2007, when I began my thesis research, the Ewing sarcoma field had made 
great progress in understanding the EWS/FLI oncogene using mutational analysis to 
demonstrate the involvement of various domains in transformation. The ETS (E26) DNA 
binding domain present in the FLI (Friend leukemia virus intergration1) portion of the 
fusion as well as the transcription regulatory domain contributed by EWS (Ewing 
sarcoma breakpoint region 1) (Delattre et al, 1992; Lessnick et al, 1995; May et al, 
1993a; May et al, 1993b; Sankar et al, 2012) is absolutely required for transformation. 
The main research focus at this time was concentrated on identifying EWS/FLI target 
genes, and the experimental system used to do this was shifting from NIH3T3 cells and 
human fibroblasts made to ectopically express EWS/FLI to a more relevant system based 
in patient derived Ewing sarcoma cell lines. In this context, authentic EWS/FLI target 
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genes could be identified by knocking down EWS/FLI using RNA interference (RNAi) 
and then re-expressing an EWS/FLI cDNA that was resistant to the RNAi effect. This 
identified thousands of genes that were dysregulated by EWS/FLI in its native cellular 
context (Smith et al, 2006). While this represented a major advancement, the cell of 
origin for Ewing sarcoma remained elusive. This limitation prevented study of the 
development of the disease by modeling tumorigenesis in vitro or using animal models.  
EWS/FLI expression results in a poorly differentiated sarcoma. This malignant 
transformation is achieved by dysregulation of thousands of target genes. Among the 
genes with aberrant expression are several genes involved in developmental signaling 
pathways such as sonic hedgehog (Beauchamp et al, 2009; Zwerner et al, 2008), 
transforming growth factor beta (Hahm et al, 1999; Sankar et al, 2012), and WNT 
(Navarro et al, 2010). Further contributing to the undifferentiated phenotype and 
unknown histogenesis, genes from multiple lineages are expressed in Ewing’s tumors. 
Principal components analysis clusters Ewing sarcoma patient tumors and cell lines with 
other primitive cell types and separate from any differentiated tissue (Tirode et al, 2007; 
von Levetzow et al, 2011). Among adult tissues, Ewing sarcoma samples have gene 
expression signatures most closely related to various brain and endothelial tissues. The 
observation that EWS/FLI induces the expression of several neural genes has led to 
debate over whether the neural gene expression reflects the cell of origin or is a 
consequence of the translocation (Staege et al, 2004).   
 The transcriptional dysregulation caused by the EWS/FLI fusion is presumed to 
be the main, or perhaps, sole driver in Ewing sarcoma development. Aside from the 
translocation, Ewing sarcoma tumors have simple karyotypes (Taylor et al, 2011). Copy 
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number analysis shows very few recurrent chromosomal gains or losses (Jahromi et al, 
2012). A more directed approach assessing known tumor suppressors, p53 and 
p16/p14ARF, demonstrated that each of these loci is mutated in less than 15% of patient 
samples, respectively (Huang et al, 2005). Mutations in known oncogenes are even less 
common. One report sequenced 29 known oncogenes in 75 Ewing sarcoma tumors and 
found that only 4% had any sequence abnormalities (Shukla et al, 2012). These studies 
suggest that there is no common cooperating mutation in this malignancy. This finding 
supports the assertion that EWS/FLI and the appropriate cellular background may be the 
only necessary factors in Ewing sarcoma development.   
 The cellular context in which this fusion occurs has proven critical in the 
formation of Ewing sarcoma. However currently the cell of origin remains undefined. 
These tumors are poorly differentiated and thought to arise in a primitive cell type. Such 
a primitive cell would contain an open chromatin structure (Gaspar-Maia et al, 2011) thus 
allowing for the massive transcriptional dysregulation caused by EWS/FLI. Over the 
years, EWS/FLI has been ectopically expressed in various cell types with different 
outcomes. EWS/FLI expression in primary mouse fibroblasts results in apoptosis 
(Deneen & Denny, 2001) and growth arrest in primary human fibroblasts (Lessnick et al, 
2002). Neuroblastoma cell lines forced to expresses EWS/FLI adopt a gene expression 
profile more similar to Ewing sarcoma than the neuroblastoma parent cell line (Rorie et 
al, 2004). Two murine-derived cells, NIH3T3 cells and bone marrow derived 
mesenchymal stem cells (MSCs), are the only cells that undergo transformation in 
response to EWS/FLI expression (May et al, 1993a; Riggi et al, 2005). To date, human 
MSCs and neural crest stem cells (NCSCs) are the only primary human cell types to 
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foster EWS/FLI expression. Importantly, however, these cells are not transformed by the 
stable expression of the translocation (Miyagawa et al, 2008; Riggi et al, 2008; von 
Levetzow et al, 2011). Despite this fact, MSCs and NCSCs, are the leading candidates for 
the cell of origin in Ewing sarcoma. Of note, NCSCs and MCSs may not be mutually 
exclusive cell types. Experimental evidence in both mouse and human cells has 
demonstrated that NCSCs can give rise to mesenchymal stem cells which can then 
differentiate along mesenchymal lineages (Lee et al, 2007; Takashima et al, 2007).  
 The majority of the Ewing sarcoma field at this time backs MSCs as the cell of 
origin. Support for this hypothesis comes from the finding that MSCs are able to maintain 
proliferation in the presence of EWS/FLI and when expressing the fusion, they take on a 
gene expression profile that resembles Ewing sarcoma cell lines and tumors (Miyagawa 
et al, 2008; Riggi et al, 2008). Complementary experimental data show the reciprocal 
effect. When EWS/FLI levels are reduced in Ewing sarcoma cell lines, the gene 
expression profile shifts toward that of a MSC (Tirode et al, 2007). This mesenchymal 
gene expression profile also correlates with a more mesenchymal phenotype marked by 
an increase in migration and adhesion with corresponding cytoskeletal rearrangements 
(Chaturvedi et al, 2012). In addition, Ewing sarcoma cells are able to differentiate along 
mesenchymal lineages when EWS/FLI is knocked-down (Tirode et al, 2007). However, 
the fact that these cells are not transformed by EWS/FLI cannot be ignored. This coupled 
with the observation that Ewing sarcoma cells cannot undergo mesenchymal lineage 
differentiation in the presence of EWS/FLI expression (Tirode et al, 2007), but MSCs 
retain this differentiation capacity when expressing EWS/FLI (Riggi et al, 2008) suggests 
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that MSCs may be further along the differentiation spectrum than the bona fide Ewing 
sarcoma cell of origin (Figure 1.1).  
 Ewing sarcoma has an undisputable relationship to the mesenchymal lineage 
while there is a less well appreciated connection to the epithelial lineage. This later 
relationship has not been investigated experimentally, but pathologists have noted 
expression of several epithelial proteins in patient tumor samples. These studies have 
noted the expression of desmosomal proteins, desmoglein and desmoplakin, tight 
junction proteins, claudin, occuldin, and tight junction protein 1 (ZO-1), and epithelial 
cytokeratins in a significant subset of samples (Machado et al, 2012; Schuetz et al, 2005). 
Despite retaining epithelial and mesenchymal features, Ewing sarcomas are 
overwhelmingly undifferentiated however these observations suggest some degree of 
cellular plasticity in these tumors.  
 Interestingly, it has recently been demonstrated that carcinomas, tumors arising 
from epithelial tissues, must retain some degree of cellular plasticity to successfully grow 
and metastasize (Ocana et al, 2012; Tsai et al, 2012). In this setting, relatively well 
differentiated epithelial tumor cells must undergo an epithelial-mesenchymal transition 
(EMT) in order to disrupt intercellular adhesions and gain invasive and migratory ability 
(Thiery, 2002). These qualities allow for escape from the primary tumor and survival in 
the circulatory system, but this does not coincide with active proliferation (Muller et al, 
2005). A mesenchymal-epithelial transition (MET) at the secondary site is proposed to 
facilitate reactivation of a proliferative state allowing for metastatic colonization. 
The contribution of EMT to cancer metastasis has been backed by research for 
some time now, but the MET in this pathologic setting has remained controversial due to 
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lack of experimental evidence. The concept of EMT and MET during development has 
been recognized for almost 50 years since they were first observed  in early chick 
embryogenesis by Elizabeth Hay and colleagues (Sartor et al, 2010). EMT and MET are 
dynamic processes that don’t necessarily refer to cell fate specification but reflect 
phenotypic changes in cell shape and mobility that occur throughout embryogenesis. 
Neural crest migration is achieved through an EMT in neuroepithelial cells of the dorsal 
neural tube. These acquired mesenchymal qualities allow for migration throughout the 
embryo until the neural crest cells undergo MET at their destination to allow for further 
differentiation into diverse tissues including neurons, melanocytes and craniofacial bones 
(Acloque et al, 2009). The induction of the developmental EMT by certain transcription 
factors and the downstream effectors is mirrored in cancer metastasis. The involvement 
of MET in tumor progression was initially only supported by pathology studies that had 
observed most epithelial tumor metastases retained the epithelial differentiation state of 
the primary tumor. This held true for metastases derived from primary tumors that had 
evidence of cells undergoing EMT – which presumably were the cells that gave rise to 
the metastases with epithelial characteristics (Brabletz et al, 2001).  
Over a decade passed before experimental evidence provided support for the 
clinically observed MET. An elegant yet simple study using a mouse model of squamous 
cell carcinoma demonstrated that as expected, expression of TWIST1, a well 
characterized EMT inducing transcription factor (EMT-TF), in the tumor resulted in the 
loss of epithelial morphology and emergence of invasive edges. The expression of the 
transgene was controlled by doxycycline (dox). When dox was applied locally, at the 
primary tumor, the cells underwent EMT at the primary site and formed pulmonary 
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metastases. These secondary lesions no longer expressed TWIST1. In contrast, when dox 
was given systemically, resulting in constitutive expression of the transgene, significantly 
fewer mice developed distant disease. The authors demonstrate that the cells 
constitutively expressing TWIST1 are present in the lung, but suggest that the expression 
of TWIST1 prevents colonization. While this forced expression is not biologically 
relevant, primary human tumor samples with matched lymph node metastases were 
consistent with this mouse model. For example, metastatic lesions expressed less than 
50% of the TWIST1 seen in the primary tumor for breast carcinomas (Tsai et al, 2012). 
An independent study recognized a similar phenomenon with a newly identified EMT-
TF, paired-related homeobox 1 (PRRX1) (Ocana et al, 2012).                            
 Sarcoma metastases do not fit neatly into this EMT-MET paradigm, but the 
concept of cellular plasticity can likely be applied more broadly. EWS/FLI prevents 
mesenchymal phenotypes, and as a result, the oncogenic driver in Ewing sarcoma 
counter-intuitively prevents cellular qualities required for metastasis (Chaturvedi et al, 
2012). In spite of this, Ewing sarcomas are highly metastatic. Approximately 20-25% of 
patients present with overt metastasis, and the remainder are considered to have 
mircometastatic disease (Arndt & Crist, 1999). This conclusion was reached in the era 
prior to the use systemic chemotherapy in Ewing sarcoma when the majority of patients 
would relapse with distant disease after surgical resection of the primary tumor (Dahlin et 
al, 1961; Wang & Schulz, 1953). Presence of metastasis correlates with very poor 
prognosis in Ewing sarcoma. Patients with localized disease have a four-year overall 
survival rate close to 90%, but this drops to less than 20% for patients with disseminated 
disease (Kolb et al, 2003). The poorly differentiated state of Ewing sarcoma retaining 
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both epithelial and mesenchymal features potentially primes these tumor cells for 
successful metastasis.   
The first broad goal of my thesis work was to understand the contributions of 
EWS/FLI target genes in “creating” a Ewing sarcoma cell. More specifically, EWS/FLI 
dysregulates the expression of thousands of transcripts; some of these genes are relevant 
to the disease process, but many are not. I had a particular interest in genes that were 
involved in developmental processes or fate specification in that they would be part of the 
bigger picture relating to Ewing sarcoma as a disease of normal development gone awry. 
I investigated B-cell chronic lymphocytic leukemia/lymphoma 11B (BCL11B), a gene 
that is up-regulated by EWS/FLI, and its contribution to the maintenance of 
transformation in Ewing sarcoma. BCL11B represented a promising EWS/FLI target 
gene for further investigation because it is one of the few genes that is regulated by 
EWS/FLI in Ewing sarcoma cell lines, in addition to the two proposed cells of origin – 
MSCs (Kauer et al, 2009) and NCSCs (von Levetzow et al, 2011). BCL11B is required 
for the normal development of skin (Golonzhka et al, 2009a), teeth (Golonzhka et al, 
2009b), the central nervous system (CNS) (Arlotta et al, 2005; Chen et al, 2008), and T-
cell maturation (Li et al, 2010) – placing it among the EWS/FLI targets involved in 
developmental processes in diverse tissues. This work is presented in Chapter 3.  
The second major goal of this work – presented in Chapter 4 - was to investigate 
genes expressed in the cell of origin that contribute to the oncogenic phenotype, again 
with a focus on developmentally relevant genes. I identified the EMT-TF zinc finger E-
box binding homeobox 2 (ZEB2), as a gene that is highly expressed in Ewing sarcoma 
patient tumors. ZEB2 expression is not regulated by EWS/FLI, and thus it is expressed in 
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the cell of origin before the translocation event, potentially contributing to a cellular 
environment permissive for EWS/FLI expression. ZEB2 represses the epithelial 
phenotype in Ewing sarcoma making its expression complementary to that of EWS/FLI 
in the formation of a tumor cell with metastatic competence. Both proteins contribute to 
the undifferentiated nature of the tumor. EWS/FLI and its targets initiate and sustain 
tumor proliferation, and ZEB2 facilitates metastasis. The work presented here highlights 
the oncogenic power of EWS/FLI, with an emphasis on developmental dysregulation, 
and the importance of the appropriate cellular context in Ewing sarcomagenesis and its 





Figure 1.1: Summary model of Ewing sarcoma cell of origin. The two proposed cells of 
origin for Ewing sarcoma are a neural crest cell or a mesenchymal stem cell. Neural crest 
cells can give rise to mesenchymal stem cells during normal development. EWS/FLI has 
been shown to repress mesenchymal features and induce neural crest and neuronal 
features. When Ewing sarcoma cells lose EWS/FLI expression they adopt mesenchymal 
gene expression profiles and the ability to differentiate along mesenchymal lineages. 
Neither neural crest cells nor mesenchymal stem cells are transformed by the expression 
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The vast majority of cancer-related deaths are attributable to metastasis. Effective 
treatment of metastatic disease will be improved by a better understanding of the 
molecular mechanisms contributing to this phenomenon. Much of the work in this field 
has focused on metastasis of carcinomas, tumors of epithelial origin, while metastasis of 
sarcomas, tumors of mesenchymal origin, remains poorly understood. Experimental 
evidence from studies in carcinomas, coupled with clinical observations, highlights the 
importance of both epithelial and mesenchymal characteristics in these cancer cells that 
make them competent for metastasis. We set out to test if similar cellular plasticity 
contributed to sarcoma metastasis. We found that the transcription factor, ZEB2, 
repressed epithelial gene expression in Ewing sarcoma cells, and this, in turn, repressed 
the epithelial phenotype. When ZEB2 was experimentally reduced in these cells, 
epithelial characteristics including decreased migratory ability and cytoskeleton 
rearrangements were observed. Furthermore, ZEB2 reduction in Ewing sarcoma cells 
resulted in a decreased metastatic potential using a mouse metastasis model. Our data 
show that Ewing sarcoma cells may have more epithelial plasticity than previously 
appreciated. This coupled with previous data demonstrating Ewing sarcoma cells also 
have mesenchymal features primes these cells to successfully metastasize. This is 
clinically relevant for two important reasons. First, this may offer a therapeutic 
opportunity to induce characteristics of one cell type or the other depending on the stage 
of the disease. Second, and more broadly, this raises questions about the cell of origin in 





Cancer metastasis is a major clinical problem with > 90% of all cancer deaths 
attributed to metastatic disease (Gupta & Massague, 2006). Metastasis is a complex, 
multistep process that results in the dissemination of cells from the site of the primary 
tumor to distant organs where these cells are able to colonize and form a secondary lesion 
(Fidler, 2003). Recent experimental evidence suggests that successful metastasis requires 
a tumor cell to possess both epithelial and mesenchymal characteristics (Ocana et al, 
2012; Tsai et al, 2012).  Epithelial features promote cell growth at both the primary and 
secondary site, while mesenchymal features contribute a migratory capacity to these cells 
facilitating escape from the tumor, the ability to survive in the circulatory system, and 
extravasate at distant sites. The vast majority of our knowledge regarding the metastatic 
cascade comes from the study of carcinomas, tumors originating from the epithelial cells. 
In this setting, epithelial tumor cells are thought to undergo an epithelial-mesenchymal 
transition (EMT) in order to disseminate from the bulk tumor, and emerging evidence 
also supports the idea that a mesenchymal-epithelial transition (MET) is required for 
colonization of distant sites (Brabletz et al, 2001; Ocana et al, 2012; Thiery, 2002; Tsai et 
al, 2012).  
Not all cancer metastases conform to this biological paradigm. Sarcomas, for 
example, are thought to arise from mesenchymal derived tissues such as bone, cartilage, 
and muscle (Helman & Meltzer, 2003), thus making it unlikely that an EMT-MET is a 
requirement in sarcoma metastasis. Several sarcomas are well differentiated and closely 
resemble what is thought to be the cell of origin (but could also be aberrantly 
differentiated), whereas others are poorly differentiated and the cell of origin remains 
uncertain (Taylor et al, 2011). A diverse group of sarcomas display features reminiscent 
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of an EMT-MET (Fitzgerald et al, 2011; Guo et al, 2007; Niinaka et al, 2010; Yang et al, 
2010) suggesting that sarcomas may have some phenotypic plasticity.      
Ewing sarcoma is an undifferentiated sarcoma characterized by the oncogenic 
fusion protein and transcription factor, EWS/FLI, and its small round blue cell 
histological presentation (Arndt & Crist, 1999). Due to its poorly differentiated nature, 
the cell of origin for this tumor is unknown. Neural crest stem cells (NCSC) (von 
Levetzow et al, 2011), mesenchymal stem cells (MSC) (Miyagawa et al, 2008) (Riggi et 
al, 2008), or perhaps neural crest-derived mesenchymal stem cells (Lee et al, 2007; Riggi 
et al, 2009; Takashima et al, 2007) are currently the most widely accepted cell of origin 
candidates. Further complicating the cellular histogenesis are the diverse locations 
including bone, most commonly the pelvis and long bones, and a variety of soft tissues 
such as kidney and pancreas, in which these tumors arise (Taylor et al, 2011). Patients 
generally present with this disease in the second decade of life and approximately 20-
25% have detectable metastatic spread at diagnosis (Arndt & Crist, 1999). Patients 
lacking overt metastasis likely harbor micrometastases as indicated by the high rate of 
relapse at distant sites following surgical resection of the primary tumor in the absence of 
systemic chemotherapy (Dahlin et al, 1961; Wang & Schulz, 1953). The presence of 
metastatic disease comes with a poor prognosis, bringing the overall survival rate from 
70-75% for localized disease to less than 20% for those with metastasis (Grier et al, 
2003). The aim of this study is to better understand the cellular plasticity in Ewing 






ZEB2 is highly expressed in Ewing sarcoma 
Metazoans are primarily composed of two cell types, epithelia and mesenchyme. 
Epithelial cells have an organized structure marked by intercellular adhesions while 
mesenchymal cells lack these cell-cell contacts and are characterized by their ability to 
migrate as single cells (Acloque et al, 2009). It is well established that Ewing sarcoma 
cells have mesenchymal features which become more pronounced upon EWS/FLI knock-
down (Chaturvedi et al, 2012; Tirode et al, 2007). Histological examination has also 
demonstrated that a subset of Ewing sarcoma patient tumor samples display epithelial 
features (Collini et al, 2001; Gu et al, 2000; Schuetz et al, 2005). Despite retaining 
remnants of these two cell types, Ewing sarcoma cells are overwhelmingly considered to 
be undifferentiated. Experimental evidence has made clear that EWS/FLI prevents the 
mesenchymal phenotype in Ewing sarcoma (Chaturvedi et al, 2012; Tirode et al, 2007), 
but the factor(s) preventing an epithelial phenotype are unknown.  
Using the Baird et al dataset that contains gene expression profiling of 19 Ewing 
sarcoma tumors (Baird et al, 2005), we confirmed variant expression of well accepted 
epithelial and mesenchymal markers (Kalluri & Weinberg, 2009). We next investigated 
the expression of the classic EMT-inducing transcription factors (EMT-TF) (Yang & 
Weinberg, 2008) (Figure 4.1A), reasoning that they represent good candidates for 
repressors of the epithelial phenotype in Ewing sarcoma. Strikingly, we found that zinc 
finger E-box binding homeobox 2 (ZEB2) (encoded by ZFHX1B, and also known as 
SMAD interacting protein 1, SIP1) was the only EMT-TF that was consistently expressed 
in Ewing sarcoma patient tumors (Figure 4.1A) and cell lines (Figure 4.1B). Many highly 
expressed genes in Ewing sarcoma are induced by EWS/FLI. However upon EWS/FLI 
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knock-down, ZEB2 expression levels do not change in the Ewing sarcoma cell lines 
tested (A673, SKNMC, TC71) (Figure 4.1C). This indicates that ZEB2 levels are not 
dependent on the translocation and thus ZEB2 may be expressed in the cell of origin.  
Accordingly, we show that ZEB2 is expressed in both proposed cells of origin, BM-MSC 
(bone marrow derived-MSC) and NCSC (Figure 4.1D) (von Levetzow et al, 2011). Much 
of the work in the Ewing sarcoma field has focused on EWS/FLI transcriptional targets, 
but a permissive cellular environment is crucial for EWS/FLI’s oncogenic ability (Kovar, 
2005), necessitating a better understanding of relevant gene expression in the cell before 
the translocation event. 
 
ZEB2 represses epithelial gene expression in Ewing sarcoma 
To determine if the expression of ZEB2 in Ewing sarcoma was indeed repressing 
epithelial gene expression, we performed genome-wide gene expression profiling using 
RNA-sequencing (RNA-seq) in A673 cells expressing a control siRNA (siControl) or 
two unique siRNAs targeting ZEB2 (siZEB2-5 or siZEB2-6) (Figure 4.2A). We found 46 
genes were up-regulated and 124 genes were down-regulated by ZEB2 using significance 
cutoffs set at a two–fold change and a false discovery rate (FDR) of 10% (Supporting 
Information Table 4.S1). We validated the RNA-seq profile by qRT-PCR of select genes 
(Supporting Information Fig 4.1). To identify functional classes that were enriched in our 
ZEB2 repressed gene list, we used the DAVID analysis functional annotation clustering 
algorithm (Huang da et al, 2009a; Huang da et al, 2009b). The most enriched term 
representing this list was epithelial cell differentiation, followed by actin binding and cell 
junction supporting our hypothesis that ZEB2 is repressing epithelial gene expression in 
Ewing sarcoma cells. E-cadherin is notably absent from our repressed gene list, as its 
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expression does not increase even in the context of ZEB2 knock-down in Ewing sarcoma 
cells. E-cadherin is a hallmark of epithelial cells. However, its absence in 97% and 100% 
of tumor samples, respectively, in two independent studies (Machado et al, 2012; Schuetz 
et al, 2005), suggests that it may be in a more permanently repressed state, and Ewing 
sarcoma cells cannot achieve full epithelial status.     
We compared the gene expression profile generated in Ewing sarcoma cells with 
reduced ZEB2 expression to gene expression data sets generated in cells undergoing 
EMT induced by different mechanisms. We first compared our ZEB2 gene expression 
profile to EMT gene expression profiles derived from human mammary luminal 
epithelial cells (HMLE) expressing TGF- or EMT-TFs, Twist, Snail1, or Goosecoid 
(GSC). (Taube et al, 2010). As expected, heat maps display an inverse expression pattern 
in ZEB2 knock-down cells undergoing some degree of MET compared to the HMLE 
cells undergoing EMT. Unsupervised hierarchical clustering also clusters the EMT cells 
apart from the siZEB2 Ewing sarcoma cells (Figure 4.2C). We confirmed this finding 
using a distinct dataset that induced EMT in HMLE cells by suppressing E-cadherin 
expression with shRNA. In this study, HMLE cells expressing an shRNA targeting E-
cadherin displayed increased migration and invasion in vitro and metastatic ability in 
mouse models. This increased metastatic potential was mediated, at least in part, by -
catenin. When cells were infected with shRNAs targeting both E-cadherin and -catenin, 
they were no longer metastatic suggesting a more epithelial state (Gautier et al, 2004). 
Consistent with these experimentally verified cell states, Ewing sarcoma cells with 
reduced ZEB2 clustered with the double knock-down HMLE gene expression profile 
(epithelial), whereas the HMLEs that had transitioned to a mesenchymal status by 
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expressing only the shRNA targeting E-cadherin had an inverse gene expression profile 
and clustered separately (Figure 4.2D).   
To validate these findings using a different cell type, we used an  EMT gene 
expression profile derived from A549 lung adenocarcinoma cells stimulated with TGF- 
and followed over a 72-hour time course (Keshamouni et al, 2009). In this model of 
EMT, western blot analysis shows that at 16 hours post-TGF- treatment mesenchymal 
markers, vimentin and N-cadherin, increase in expression while E-cadherin expression 
begins to decrease indicating the start of the EMT (Keshamouni et al, 2006). Strikingly, 
our ZEB2 knock-down gene expression data displays an expression signature similar to 
the early time points (0.5 - 4 hours) which represents an epithelial cellular state. At 8 
hours, the A549 gene expression profile starts to shift, and at 16 hours, a time point when 
the EMT has occurred based on the western blot analysis, the gene expression pattern is 
completely reversed (compared to our ZEB2 knock-down dataset) – representing a 
mesenchymal cellular state (Figure 4.2E).  These transcriptional profiling comparisons 
demonstrate that Ewing sarcoma cells and epithelial cells regulate a similar panel of 
genes to achieve cellular plasticity.  
 
ZEB2 represses the epithelial phenotype in Ewing sarcoma 
To further study the gene expression changes seen by RNAseq, we designed a 
retroviral shRNA targeting the 3’UTR of ZEB2 to achieve stable knock-down in Ewing 
sarcoma cell lines. This construct reduced ZEB2 RNA and protein levels (Figure 
4.3A,B). Using this shRNA, we examined the transcript changes of several genes 
identified as ZEB2 repressed targets. It has been suggested that total ZEB (ZEB1 and 
ZEB2) levels in a cell are interdependent and that there is some ability to compensate 
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between ZEB1 and ZEB2 (Park et al, 2008). In agreement with this hypothesis, we saw 
that knock-down of ZEB2 led to an increase in ZEB1 expression in three Ewing sarcoma 
cell lines (A673, SKNMC, and TC71). We also verified the ZEB2 mediated repression of 
several epithelial genes in A673 cells including desmosome components, desmoplakin 
(DSP) and plakophilin 2 (PKP2), an intermediate filament characteristic of simple 
epithelia, keratin 8 (KRT8), the tight junction protein, F11 receptor (F11R, also known as 
junctional adhesion molecule A, JAM-A) and a facilitator of cytoskeletal remodeling, 
Rho guanine nucleotide exchange factor 5 (ARHGEF5). ZEB2 repressed these genes to a 
lesser degree and not as consistently in two other Ewing sarcoma cell lines, SKNMC and 
TC71 (Figure 4.3A). KRT8 and DSP protein levels changed consistently with what was 
seen at the RNA level (Figure 4.3B). The concomitant increase in ZEB1 expression with 
ZEB2 knock-down may be responsible for the lack of expression of some epithelial genes 
in other cell lines – for example, KRT8 in SKNMC cells (see below, Figure 4.4B). 
Indeed, ZEB1 and ZEB2 can bind similar DNA sequences and have some redundant 
function (Postigo & Dean, 2000).       
In vitro functional assays were performed to ask whether the increase in epithelial 
gene expression realized upon ZEB2 knock-down resulted in a more epithelial phenotype 
in Ewing sarcoma cell lines. Boyden chamber assays (Figure 4.3C) and wound-healing 
assays (Figure 4.3D) were used to define the migratory capacity of Ewing sarcoma cells. 
In both settings, Ewing sarcoma cells displayed reduced migratory ability upon ZEB2 
knock-down. For the Boyden chamber assay cells were plated in serum free media in the 
upper chamber, and induced to migrate toward serum containing media in the bottom 
chamber. As a control for this assay, cells from each condition were plated in serum-free 
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media and counted 24 hours later to eliminate the possibility that differences in the cell’s 
ability to survive under serum-free conditions contributed to the phenotype (Supporting 
Information Fig 4.2). The wound healing invasion pattern of cells with reduced ZEB2 
shows a slower and more cohesive movement which is characteristic of epithelial cells. In 
contrast, A673 and SKNMC control cells demonstrate a more mesenchymal migration 
pattern marked by single cells invading the wounded area and faster wound closure.  
Epithelial and mesenchymal cells have unique cytoskeletal arrangements. Using 
phalloidin to label F-actin, we show that A673 cells expressing an siRNA targeting ZEB2 
traded a more diffuse actin cytoskeleton for more compact actin rings with a cobblestone 
morphology typical of epithelial cells. We also confirm the knock-down by the absence 
of ZEB2 nuclear staining in the siZEB2 transfected cells (Figure 4.3E). Taken together, 
the increase in epithelial gene expression upon ZEB2 reduction, allows for phenotypic 
and morphological changes consistent with an epithelial shift.   
 
Ectopic expression of miR-200 family epithelializes Ewing sarcoma cells 
The relationship between ZEB1 and ZEB2 and the miR-200 family of micro-
RNAs (miRNA) (miR-200a, miR-200b, miR-200c, miR-141 and miR429) is well 
established (Gregory et al, 2008; Park et al, 2008). These miRNAs bind to the 3’UTR of 
ZEB1 and ZEB2 to repress translation; conversely, ZEB1 and ZEB2 can bind to the 
promoters of miR-200s to repress transcription. This double-negative feedback loop is 
thought to serve as a switch to regulate EMT – when ZEB levels are high and miR-200 
levels are low, then cells are phenotypically mesenchymal, and when the reverse is true, 
then cells are more epithelial (Brabletz & Brabletz, 2010). We used this phenomenon to 
investigate whether Ewing sarcoma cells could be induced to epithelialize by a 
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mechanism that was distinct from RNAi methods previously tested, yet still dependent on 
ZEB2 levels.  
We ectopically expressed the polycistronic miR-200 gene cluster from 
chromosome 1 (miR-200b, miR200a, and miR429) in A673 and SKNMC Ewing sarcoma 
cells (Figure 4.4A). As predicted, expression of miR-200 family members reduced the 
expression of ZEB2 protein (Figure 4.4B). Epithelial proteins, DSP and KRT8, were also 
increased in miR-200 expressing A673 and SKNMC cells. Notably, KRT8 expression 
was not observed when ZEB2 was specifically knocked-down in SKNMC cells (Figure 
4.3B). This discrepancy may result from the repression of ZEB1 by the miR-200 family, 
in contrast to the compensation by ZEB1 when ZEB2 is specifically reduced. 
Furthermore Ewing sarcoma cells expressing miR-200s display a migration defect in 
wound-healing assays (Figure 4.4C) similar to that of cells with specific reduction of 
ZEB2 using shRNA (Figure 4.3D). The epithelial plasticity of Ewing sarcoma cells 
expressing miR-200 family members complements our findings implicating ZEB2 in the 
repression of the epithelial phenotype. 
 
ZEB2 facilitates metastasis in Ewing sarcoma 
We have established the ability of ZEB2 to repress epithelial features in Ewing 
sarcoma cells and the re-emergence of such features upon ZEB2 knock-down. We 
hypothesized that this innate epithelial repression primes Ewing sarcoma cells for 
metastasis, and thus if ZEB2 levels were reduced, Ewing sarcoma cells would lose the 
ability to metastasize. To test this hypothesis, we used an orthotopic mouse metastasis 
model whereby Ewing sarcoma cells are injected intratibially and cells spontaneously 
metastasize to the lung (Guan et al, 2008). This model accounts for all steps in the 
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metastatic cascade from escaping the primary tumor to colonizing the secondary site, 
making it superior to the tail vein injection metastasis model. Two doses of A673 cells 
(25K or 100K) infected with a retroviral shRNA targeting ZEB2 or control shRNA were 
injected into the right tibia of male NOD-SCID mice. Tumor growth was monitored 
weekly by measuring the right tibia using calipers. Mice were sacrificed at 6 weeks post-
injection, and the lungs were harvested. ZEB2 knock-down had no effect on tumor 
growth (Figure 4.5A). Fewer mice injected with A673 cells expressing the ZEB2 shRNA 
showed macroscopic pulmonary metastases at both doses; however, this binary 
comparison did not yield statistical significance (Figure 4.5B). It was clear by gross 
observation that the metastatic burden was much greater in the control shRNA injected 
animals compared to the ZEB2 shRNA injected animals (Figure 4.5C). When the area of 
the lung with metastatic lesions was quantified, ZEB2 knock-down cells showed 
significantly less metastatic burden (Figure 4.5D and Supporting Information Fig 4.3). 
Importantly we saw no difference in tumor size and no correlation between tumor size 
and propensity to metastasize (Figure 4.5E) indicating ZEB2 does not play a role in 




Sarcoma metastasis is not well understood. Sarcomas are thought to arise from 
mesenchymal cells and thus do not have a baseline epithelial differentiation state that is 
seen in many carcinomas. This fact excludes sarcomas from the EMT-MET metastasis 
paradigm whereby tumor cells in carcinomas must lose their epithelial features to escape 
the primary tumor, but regain them in order to colonize the secondary site. However, it is 
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likely that the concept of cellular plasticity in metastasis can be applied to sarcomas. 
Undifferentiated Ewing sarcoma cells may innately have the right balance of epithelial 
and mesenchymal features that allow for successful growth at the primary and secondary 
sites, as well as a high propensity for metastasis. Providing support for this intrinsic 
ability, micrometastatic spread is nearly ubiquitous in Ewing sarcoma patients and occurs 
at early stages of the disease (Spraker et al, 2012) suggesting a parallel progression of 
tumor and metastases (Klein, 2009). This is in stark contrast to some carcinomas such as 
colorectal cancer where a slow progression and accumulation of mutations eventually 
leads to an invasive malignancy (Fearon & Vogelstein, 1990). A “passive metastasis” 
model has recently been proposed for Ewing sarcoma dissemination to contrast the 
deliberate steps necessary in carcinoma metastasis (Chaturvedi et al, 2012). 
The passive metastasis model predicts that Ewing sarcoma cells have weak 
intercellular adhesions and ample access to the bone marrow and circulatory system due 
to their bone-associated locations. This puts tumor cells in a prime position to enter the 
blood stream and colonize the secondary site, most frequently lung and bone. This is 
consistent with our data showing that reduction of ZEB2 increases epithelial features and 
cell-cell adhesion. Ewing’s tumors are then in a less passive state and therefore a 
decrease in metastatic potential is achieved. The fundamental ability of Ewing sarcoma 
cells to proliferate as well as metastasize may also contribute to the limited latency (72% 
of relapse occur within two years of diagnosis and 94% within five years) seen in Ewing 
sarcoma (Stahl et al, 2011). According to the EMT-MET metastasis model, colonization 
(the ability to form a macroscopic secondary lesion) is the limiting step in the multistep 
metastatic cascade. In this setting, circulating tumor cells are plentiful, and some are able 
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to seed the secondary site. However these cells are quiescent, marked by the absence of 
Ki-67 staining (Chambers et al, 2002; Muller et al, 2005). A subsequent event, the 
proposed MET, is then necessary for these cells to re-enter into the cell cycle. This has 
been used to explain the long latency often seen in breast cancer recurrence (Meng et al, 
2004; Pantel et al, 2008). 
Genetic Type II Metastasis was proposed by Brabletz to explain undifferentiated 
carcinoma metastases (Brabletz, 2012). In this model, poorly differentiated primary 
tumors that arise in primitive cell types give rise to undifferentiated metastases. These 
malignancies don’t rely on EMT-MET for metastasis because their primitive state 
endows them with an intrinsic EMT phenotype. Other characteristics of cancers of this 
type include a high propensity for metastasis at early stages of the disease, limited 
latency, and the presence of a genetic alteration which contributes to a fairly fixed cell 
state that is compatible with tumor growth and metastasis. Ewing sarcoma metastasis 
conforms to this model. Ewing sarcoma is thought to occur in a primitive cell type where 
the genetic alteration, EWS/FLI, prevents mesenchymal differentiation and ZEB2 
prevents epithelial differentiation, as demonstrated here. Metastasis is a frequent and 
early event in Ewing sarcoma compatible with the idea that EMT is not needed. The 
presence of overt metastasis at presentation coupled with the limited latency seen in this 
disease also supports a model where MET is not a limiting factor in colonization of the 
secondary site. 
The cell of origin for Ewing sarcoma is unknown, but it is thought to be a NCSC 
or MSC. We show that ZEB2 is expressed in both of these primitive cells. It should be 
noted that these two cell types may not be mutually exclusive. Experimental evidence has 
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described the isolation of NCSCs from human embryonic stem cells which can be 
directed to differentiate along mesenchymal lineages in addition to neurons and Schwann 
cells (Lee et al, 2007). Studies show that experimental reduction of EWS/FLI, causes 
Ewing sarcoma cells to resemble MSCs both in gene expression and differentiation 
capacity (Tirode et al, 2007). This coupled with evidence that ectopic expression of 
EWS/FLI in human MSCs leads to a Ewing sarcoma gene expression signature has 
supported MSCs as the cell of origin. However, hMSCs expressing EWS/FLI are not 
transformed (Riggi et al, 2008). Ewing sarcomas have a relatively low frequency of 
mutations in known tumor suppressors and oncogenes supporting the concept that 
EWS/FLI is the main oncogenic driver in this malignancy (Huang et al, 2005; Shukla et 
al, 2012). If this is true, EWS/FLI alone should induce transformation if expressed in the 
correct cell of origin. 
We propose an alternate, yet integrative, hypothesis for tumorigenesis in Ewing 
sarcoma: the EWS/FLI translocation occurs in a cell that is undergoing a normal 
developmental EMT. In this model, ZEB2 is expressed in a neural crest or 
neuroepithelia-derived progenitor cell to induce a developmental EMT. The EWS/FLI 
translocation can be acquired at various stages of this transition and blocks further 
mesenchymal differentiation, resulting in an undifferentiated Ewing sarcoma cell. 
Support for this model comes from the role of ZEB2 during development. ZEB2 is 
expressed in the developing neural crest and neural epithelium. The homozygous ZEB2 
knock-out mouse is embryonic lethal due to defects in neural crest migration seen on 
embryonic day 8.5 (Van de Putte et al, 2003). This model is also consistent with the well 
characterized ability of EWS/FLI to prevent mesenchymal differentiation (Chaturvedi et 
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al, 2012; Tirode et al, 2007; Torchia et al, 2003), and may help to reconcile the 
observation that Ewing sarcoma cell lines can only differentiate along mesenchymal 
lineages in the absence of EWS/FLI (Tirode et al, 2007), while MSCs, being further 
along the differentiation spectrum than the Ewing sarcoma cell of origin, retain this 
ability even when expressing EWS/FLI (Riggi et al, 2008). Expression of EWS/FLI in 
human pediatric bone marrow derived MSCs (Riggi et al, 2010) as well as neural crest 
derived MSCs (von Levetzow et al, 2011) results in repression of MSC genes while 
increasing expression of NCSC genes which could reflect a de-differentiation, in line 
with our proposal that the cell of origin is a precursor to a MSC. 
Strong evidence to support this concept also comes from the finding that neural 
crest cells and neuroepithelial cells are the initial source of MSCs from mouse embryonic 
stem cells in vitro (Takashima et al, 2007). This group went on to show that P0+ neural 
crest cells and Sox1+ neuroepithelial cells gave rise to MSCs during normal mouse 
development. Interestingly, in lineage tracing studies, these neural crest and 
neuroepithelial derived MSCs were present at low abundance in bone cell preparations 
from femoral and tibial bones of neonates, 4-week and 12-week-old-mice, and this 
population of cells decreased with age (Takashima et al, 2007). This places these cells in 
the proper space and time to serve as the cell of origin for Ewing sarcoma. Of relevance 
to the present study, desmosomes are abundant in neuroepithelium (Gallicano et al, 
2001), and KRT8 is also expressed in early embryonic epithelial tissue (Dellagi et al, 
1987; Jackson et al, 1981; Viebahn et al, 1995). 
A mouse model for Ewing sarcoma has remained elusive, despite several attempts 
(Codrington et al, 2005; Lin et al, 2008; Torchia et al, 2007). One possible reason for this 
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is that EWS/FLI has not been expressed in the appropriate precursor cell. One prediction 
based on the model presented in this paper is that perhaps expression of EWS/FLI driven 
by the Zeb2 promoter in conjunction with the Sox1 promoter would allow for relevant 
spatial and temporal expression of this translocation. Based on the mouse expression 
studies of ZEB2 and its role as an EMT-TF, ZEB2 expression would mark the EMT of a 
neural crest cell or neuroepithelial cell and thus provide a cellular intermediate to a 
NCSC and a MSC. 
Here we show that Ewing sarcoma cells express high levels of the EMT-TF, 
ZEB2, and that this transcription factor represses epithelial gene expression and epithelial 
phenotypes in Ewing sarcoma cells. Reduced ZEB2 expression results in the re-
expression of genes involved in epithelial differentiation and the formation of 
intercellular junctions concomitant with a decrease in cell migration in vitro and 
decreased metastatic potential in vivo. We have proposed a model for Ewing’s 
sarcomagenesis whereby the EWS/FLI translocation occurs in a cell undergoing a ZEB2 
induced developmental EMT. This leaves the cell “stuck” in between an epithelial 
differentiation state (prevented by ZEB2 expression) and a mesenchymal differentiation 
state (prevented by EWS/FLI expression). This poorly differentiated cancer cell is now 
poised for successful growth in the primary and secondary sites, owing to its epithelial 
features, while at the same time made competent for metastasis by its mesenchymal 
features (see model Figure 4.6). In the future it will be interesting to investigate the 
ability of Ewing sarcoma cells to “toggle” expression of EWS/FLI and ZEB2 depending 
on their stage in the metastatic process to accentuate either epithelial or mesenchymal 
traits, reminiscent of what has been proposed to achieve EMT-MET in carcinoma 
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metastasis. This cellular plasticity may offer a therapeutic opportunity, if cells can be 
forced toward one lineage or the other depending on the stage of the disease. 
 
Materials and methods 
Constructs 
shRNA targeting EWS/FLI (EF2 shRNA), or control (control shRNA) targeting 
luciferase or ERG (which is not expressed in these cells) have been previously described 
(Smith et al 2006). shRNA was designed targeting the 3’UTR of ZEB2 (Supporting 
Information Table 4.S2) and cloned into pMKO.1 puro retroviral vector (Masutomi et al 
2003). ON-TARGETplus siRNA targeting the ORF of ZEB2 (siZEB2-5, siZEB2-6) and 
nontargeting siRNA (siControl) were purchased from Thermo Scientific. Lentiviral 
microRNA precursor constructs (miR-control, miR-200,a,b,429) were purchased from 
System Biosciences.  These constructs were also modified by subcloning a CMV 
promoter and puromycin resistance cassette downstream of the miRNA precursor to 
allow for antibiotic selection.   
 
Cell culture 
Ewing sarcoma cell lines A673, SKNMC, (ATCC) and TC71 (a gift from 
Timothy Triche, Children’s Hospital Los Angeles) were grown as previously described 
(Lessnick et al, 2002; Wiles et al, 2013). For retroviral plasmids, control shRNA (LUC or 
ERG) and ZEB2 shRNA, cells were infected and selected in the appropriate antibiotic 
selection media resulting in a polyclonal population. For lentiviral vectors, miR-control 
and miR-200 family, cells were infected and selected with the appropriate antibiotic 
selection media or sorted for GFP+ cells using a FACSAria (BD Biosciences). 
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Transfections with siRNA were preformed according to the manufacturer’s instructions 
(Thermo Scientific) at final concentration of 25 nM.        
 
Quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR) 
Total RNA was extracted with an RNAeasy kit (Qiagen).  mRNA (30 ng) was 
quantitated by SYBR green (BIO-RAD) using one-step qRT-PCR with gene specific 
primers. Messenger RNA was reverse-transcribed at 50°C for 10 minutes followed by a 5 
minute denaturation at 95°C and then 45 cycles of PCR (95°C for 30 seconds, 57°C for 
30 seconds, 72°C for 30 seconds). For miRNA quantification, total RNA was extracted 
using the mirVana miRNA isolation kit (Ambion). RNA (10 ng) was reverse-transcribed 
using the Taqman Micro-RNA Reverse Transcription Kit and miRNA specific primers 
(Applied Biosystems) at 16°C for 30 minutes, 42°C for 30 minutes, followed by 5 
minutes at 85°C in a BIO-RAD DNA engine Peltier thermal cycler. The reverse-
transcribed DNA was then used for qPCR with Taqman small RNA assay miRNA 
specific probes (Applied Biosystems) with the following cycling parameters: 95°C 10 
minutes, and 40 cycles of 95°C for 15 seconds and 60°C for 1 minute. Fold change was 
determined using the ∆Ct method comparing all samples to the control after normalizing 
to GAPDH (for mRNA) or snRNA U6 (for miRNA) or expression was determined as a 
percent of GAPDH expression, as indicated. qPCR and qRT-PCR were performed using 
the BIO-RAD MyiQ single color real-time PCR detection system.  
 
RNA sequencing 
RNA from A673 cells transfected with siZEB2-5, siZEB2-6 or siControl 72 hours 
post-transfection was extracted with the RNAeasy kit (Qiagen) and treated with DNAse.  
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Two biological replicates per condition were used to construct libraries for high-
throughput sequencing according to the manufacturer’s instructions (Illumina) and 
sequenced on the Illumina Hi-Seq with 50 cycles of single end reads.  Sequences were 
aligned to the human genome build hg19. The RNAseq data from this publication has 
been submitted to the US National Center for Biotechnology Information-Sequence Read 
Archive (NCBI-SRA) and assigned the accession number SRP022361.  Differential gene 
expression (siControl vs siZEB2-5,-6) was determined using the publically available 
USeq package (useq.sourceforge.net).  Significance parameters were set at an FDR of 
10% and two-fold change.  
 
Comparison of RNA-seq with microarray data 
Microarray data from Sartor et al (2009) (PMID 20007254, GEO accession 
GSE17708, platform hgu133plus2), Onder et al (2008) (PMID 18483246, GEO accession 
GSE9691, platform ht_hgu133a), and Taube et al (2010) (PMID 20713713, GEO 
accession GSE24202, platform ht_hgu133a), were downloaded as raw CEL files from 
GEO (www.ncibi.nlm.nih.gov/geo).   Fluorescent intensities were extracted and 
normalized by RMA as implemented in the Bioconductor package affy (Gautier et al, 
2004) and cdf and annotation packages appropriate to their platform.  Differential gene 
expression (DGE) among published conditions (control vs treatment/cDNA/shRNA) was 
determined using the Bioconductor package limma and obtaining the log2 fold change 
(log2FC) from the top statistically significant differentially expressed genes. Genes from 
these sets were intersected with log2FC values of corresponding genes from the ZEB2 
knock-down RNA-seq.  The only genes allowed from the ZEB2 knock-down RNA-seq 
were those having a p-value for DGE less than 0.05.  Final sets were derived by further 
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requiring that the absolute log2FC DGE be greater than one for at least one of the 
conditions in the comparison.  For the purposes of DGE comparison, heat maps were 
made from the results of standardizing column values followed by hierarchical clustering 
using Euclidean distance and complete linkage.  Both row and column clustering were 
performed except in the case of Sartor et al where the sample order follows a time course. 
 
Migration assays 
Boyden chambers were performed using cell inserts with m pores (BD 
Biosciences). Fifty-thousand cells were seeded in serum-free media in the upper 
compartment of a fibronectin (1g/mL) coated chamber which was placed into a well 
containing media with 10% serum. Cells were allowed to migrate for 24 hours before 
fixation in methanol and staining with modified Giesma stain (1:10). Each condition was 
done in triplicate and five fields from each chamber were imaged at 10x using an 
Olympus IX81 microscope with CCD camera and DP Controller imaging software. 
Wound healing assays were performed by plating each condition in triplicate in six well 
plates and growing to ~90% confluence. Monolayer wound was created with a 
micropipette tip, washed 4x with PBS and grown in appropriate media containing 5% 
serum. Cells were washed twice with PBS and given fresh media before imaging. Phase 
contrast images were taken at 0, 24, 48, 72, and 96 hours on a Ziess Axiovert100 at 10x 
magnification with a Q imaging MicroPublisher 5.0 RTV camera using QCapture Pro7.0 
imaging software. The area of the wound at each time point was measured using the 






Western blots were performed using standard protocols with 4-15% gels, 
nitrocellulose membranes and developed with home-made enhanced chemiluminescence 
(ECL). The following antibodies were used: DSPI+II (Abcam 71690), KRT8 (Abcam 
9023), Tubulin (Calbiochem CP06), ZEB2 (Active Motif 61095).    
 
Immunofluorescence 
A673 cells were plated on fibronectin (10g/mL) coated coverslips 48 hours post 
transfection. Twenty-four hours after plating, cells were fixed in 3.7% formaldehyde.  
Fixed cells were blocked and permeablized with PBST-BSA (0.1% triton-x100 and 0.5% 
BSA). Cells were incubated for 1 hour at 37°C in a moist chamber with ZEB2 antibody 
(Active Motif 61095) (1:100), washed for 15 minutes in PBST-BSA, followed by 
incubation with AlexaFluor-568 secondary antibody (1:100), AlexaFluor-488 phalloidin 
(1:50) (Invitrogen) and DAPI (1g/mL) for 1 hour at 37°C in a moist chamber. Cells 
were washed and mounted in FlouromountG (Southern Biotech).  Cell images were 
captured using a Zeiss Axioskop2 mot plus microscope with a 40x plan NA 0.75 
NeoFluor objective, Zeiss Axiocam MR camera, and Zeiss Axiovision v4.8.1 software 
(Carl Zeiss MicroImaging, Inc.). The following exposure times were used for the 
displayed images: 405 nm (DAPI) – 10 ms, 488 nm (Phalloidin) – 400 ms, 568 nm 
(ZEB2) – 600 ms. 
 
Tibial injection metastasis model 
All animal studies were performed in accordance with protocols approved by the 
University of Utah Institutional Animal Care and Use Committee. Male NOD-SCID mice 
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(kindly provided by Alana Welm) were 6-7 weeks old at the time of injection. A673 cells 
were retrovirally infected with either a control shRNA or ZEB2 shRNA and selected in 
puromycin. Cells were counted and resuspended in growth factor reduced Matrigel 
matrix (BD Biosciences). After boring a hole in the tibia with a 26-gauge needle, 10 
microliters of Matrigel containing 25K or 100K cells were injected into the right tibia 
using a glass Hamilton syringe. Tibial measurements using calipers were performed 
weekly to follow the growth of the tumors. Mice were sacrificed at 6 weeks and the lungs 
were harvested to evaluate for metastases.  Mice that were sacrificed before the 6-week 
endpoint of the study due to a primary tumor size >2 cm in one direction and mice with 
no detectable primary tumor were excluded from the study. 
 
Tissue processing 
The lungs were washed in PBS and stored in 10% formalin immediately after 
harvesting. Samples were fixed in 10% formalin at 4°C for 24 hours.  Lungs were then 
washed 3x with PBS and stored in 70% ethanol at 4°C. Whole lung images were acquired 
using an Olympus MVX10 dissecting microscope at 0.63x, Spot insight Firewire 4 
camera, and Spot Alias imaging software. Area of whole lung and metastasis (front and 





Figure 4.1: ZEB2 is expressed in Ewing sarcoma cells.  
A. Gene expression data from Ewing sarcoma patient tumors from the Baird et al dataset 
showing the expression of epithelial markers, E-cadherin (CDH1), tight junction protein 
1 (ZO-1), lamanin beta 1 (LAMB1), and mucin 1 (MUC1), mesenchymal markers, N-
cadherin (CDH2), vimentin (VIM), fibronectin (FN), and integrin alpha 5 (ITGA5) , and 
EMT-TF, Snail1 (SNAI1), Snail2/Slug (SNAI2), TWIST1, ZEB1 and ZEB2. B. qRT-
PCR data showing the expression of EMT-TF in a panel of Ewing sarcoma cell lines – 
A673, RDES, SKNMC, TC71, TC32, CHLA10 and CHLA258. C. qRT-PCR data 
showing EWS/FLI and ZEB2 expression levels in control shRNA and EWS/FLI shRNA 
infected Ewing sarcoma cell lines A673, SKNMC, and TC71. Errors bars represent 
standard deviation (SD) from three technical repeats. D. ZEB2 gene expression in hBM-
MSC and hNCSC from the von Levetzow et al data set. Error bars represent SD. 
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Figure 4.2: ZEB2 represses epithelial gene expression in Ewing sarcoma cells.  
A. qRT-PCR data and western blot showing ZEB2 expression levels in A673 cells 
transfected with control siRNA or two different siRNAs targeting ZEB2 (siZEB2-5 and 
siZEB2-6). Tubulin is shown as a loading control. B. Graph showing the top ten enriched 
terms by DAVID analysis in the ZEB2 repressed gene set from our RNAseq analysis. 
Enrichment score equals –log(mean P-value). C. Heat map and hierarchical clustering of 
the ZEB2 RNAseq data with Taube et al EMT data in HMLE cells. D. Heat map and 
hierarchical clustering of the ZEB2 RNAseq dataset compared to the Onder et al EMT 
dataset in HMLE cells. E.  Heat map of the ZEB2 RNAseq data with Keshamouni et al 







 Figure 4.3: ZEB2 represses the epithelial phenotype in Ewing sarcoma cells.  
A. qRT-PCR data showing ZEB2 knock-down in A673, SKNMC, and TC71 cells 
infected with control shRNA or shRNA targeting ZEB2 and the corresponding change of 
expression in the indicated genes. Error bars represent SD from technical triplicates. B. 
Western blot showing expression of ZEB2, KRT8, and DSP in A673, SKNMC, and 
TC71 cells expressing a control or ZEB2-targeting shRNA. Tubulin is shown as a loading 
control. C. Boyden chamber cell migration assays in A673, SKNMC, and TC71 cells 
infected with a control shRNA or ZEB2 targeting shRNA. Data are from two independent 
experiments each done in triplicate. Each point represents cells counted in one field – five 
fields were counted per chamber. Significance was determined by Student’s T-test and 
the mean is shown. D. Representative images from three time points of a wound healing 
assay using control or ZEB2 shRNA infected A673 and SKNMC cells (left). Scale bar = 
250m. Quantification of the area of the wound healed measured every 24 hours (right). 
Data is the average of two independent experiments each done in triplicate (n=6). P-
values indicated above each condition as determined by Student’s T-test and error bars 
show SD. E. Immunofluorescence images showing ZEB2 expression levels (red - 568 
nm) and actin cytoskeleton stained with phalloidin (green - 488 nm) in A673 cells 









Figure 4.4: Expression of miR-200 family members epithelializes Ewing sarcoma cells. 
A. qRT-PCR data showing the expression of the indicated miRNA in A673 and SKNMC 
cells infected with a lentivirus expressing a control miRNA or miR-200 family cluster 
from chromosome 1 (miR-200b, miR-200a, miR-429). Error bars represent SD from 
three technical repeats. B. Western blot showing expression of ZEB2, KRT8, and DSP in 
A673 and SKNMC cells expressing a control miRNA or miR-200 family cluster from 
chromosome 1 (miR-200b, miR-200a, miR-429). Tubulin is shown as a loading control. 
C. Representative images from three time points of a wound healing assay using control 
miRNA or miR-200 family cluster from chromosome 1 (miR-200b, miR-200a, miR-429) 
infected A673 and SKNMC cells (left). Scale bar = 250m. Quantification of the area of 
the wound healed measured every 24 hours (right). Data are the average of two 
independent experiments each done in triplicate (n=6). P-values indicated above each 








Figure 4.5: Reduction of ZEB2 decreases metastatic potential in Ewing sarcoma cells.  
A. Volume of the right tibia from mice 6 weeks postinjection with either 25K or 100K 
control or ZEB2 shRNA (as indicated) infected A673 cells. B. Pie charts showing the 
total number of mice with macroscopic metastatic lung lesions at the time of sacrifice (6 
weeks postinjection). Combined data include both 25K and 100K conditions. C. Images 
of lungs (front and back) from the animal from each condition bearing the highest 
metastatic burden. Scale bar = 5mm. D. Graph showing the percent of the lung containing 
macroscopic pulmonary lesions in each condition, as indicated. P-value determined by 
Wilcoxon Mann Whitney test. E. Correlation of metastatic burden (y axis) and tumor size 












Figure 4.6: Model for ZEB2 in Ewing sarcoma. 
ZEB2 prevents epithelial differentiation and EWS/FLI prevents mesenchymal 
differentiation. This leaves a Ewing sarcoma cell “stuck” between these two cell lineages 





Figure 4.S1: RNA-seq validation 
A. qRT-PCR data to validate the ZEB2 RNA-seq dataset: ZEB2 repressed genes (top) 







Figure 4.S2: No difference in cell viability in serum free media between control and 
ZEB2 knock-down cells. 
A. Cell counts for A673, SKNMC, and TC71 cells infected with a control shRNA or 
shRNA targeting ZEB2. Cells (2x106) were plated in serum-free media and grown for 24 
hours before counting in trypan blue. Graphs represent two independent experiments 





Figure 4.S3: Pulmonary metastatic burden. 








        Table 4.S1: ZEB2 regulated genes as determined by RNAseq  
 
 
ZEB2 Repressed Genes ZEB2 Upregulated Genes 
SFN RND1 CALCA COL3A1 MT1G CAPN5 
BC070061 PRKCZ INADL CMKLR1 OLFML2B MT2A 
KIAA1543 ABCC3 SLC16A14 COL1A1 CTHRC1 MT1E 
CHI3L1 PHACTR2 HPGD MRGPRF NOTCH3 MMP2 
GPR87 SCEL MARVELD3 ACVRL1 KAAG1 COL6A1 
F11R RBM47 PLIN4 IGDCC4 ANGPTL2 C3AR1 
TNS4 RBP7 SLC22A5 TLR7 NRXN2 CNRIP1 
MMP13 MMP3 TMEM90B CSPG4 TMEM55A MT1F 
SPINT2 KRT80 CORO2A TMEM100 PCDH18 BX649164 
MYO5B LAMA4 PDE6A GAP43 COL1A2 MT1X 
DSP PLS1 EPPK1 DCN PGF CDKL5 
EXPH5 FBXO2 NIPAL3 DKK3 THY1 EMILIN1 
NCF2 ITGA2 ID1 CRYAB SRPX2 CSF1 
AKR1B10 HEBP2 PPP1R1C MT1H SYT11 GPNMB 
CEACAM5 TNK1 MCOLN3 LOXL2 CREB3L1  
ZEB1 RHOD KIAA1244 ABCA1 EDEM2  
C10orf35 SPINT1 HLA-DMB    
TPD52L1 C3orf52 RAB11FIP4    
CLEC7A SMR3B CNTNAP2    
ARHGEF5 RPS6KA1 C11orf52    
ANXA3 MMP12 TMEM84    
SYNGR4 RNF125 IL2RG    
TC2N FGFBP2 KCNE3    
C8orf47 LMTK3 GYLTL1B    
ARHGEF5L CYP2S1 AHRR    
SH2D3A CACNA1I CBX7    
F2RL1 NIPAL1 ANKRD5    
LOC220930 MAP7D2 SHF    
TSPAN15 BAIAP2L1 SYT12    
CHMP4C C19orf51 PKP2    
KIF21A GRM2 GOLGA8B    
KRT8 TMEM144 TRA    
ELOVL7 SULT1E1 CD79A    
SMPDL3B C3 PHKA1    
ALOX12E LCP1 HIP1R    
COL17A1 HKDC1 LAMB3    
RAET1E AF289551 PLCH1    
AGPAT9 LRAT TXNRD1    
IL28RA CDS1 BCAR3    
IRF6 RNF144B     
CDCP1 PAIP2B     
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GENE FORWARD PRIMER (5’-3’) REVERSE PRIMER (5’-3’) 
ZEB2 CAGCACCAAATGCTAACCCAAGGAG CACCACTGTGAATTCGCAGGTGTTC 
SFN GCGCATCATTGACTCAGCCCGG GAGTCCTCGCTGAGGGTGTGC 
MMP13 CCAGTTTGCAGAGCGCTACCTG CACATCAGGAACCCCGCATCTTGG 
ZEB1 GGAAGAGATCAAAGACATGTGACGC GCTTATGTGTGAGCTATAGGAGCCAG 
TSPN15 CCACCGTGTTCTGGCTGATTGG CCCAAGGATGTACATGAATGCTTGG 
PKP2 CGTGGGCAACGGAAATCTTCACC GGCAGTTGTGCCAGCCTTTAGC 
DSP CGGCTACTGTCAAACCGGCACG CTCCATACTTCAATTCAGGCTGCACG 
TPD52L1 GCGCAGGCACAAGGTTTGTTGG GCAGTGGTAGTCTGCATGTCATGC 
F11R GCGATCCTGTTGTGCTCCCTGG CCGGTCCTCATAGGAAGCTGTG 
MMP3 GGACAAAGGATACAACAGGGACC CAGGGGGAGGTCCATAGAGGG 
KRT80 CCATCTATGAGCAGGAGCTGAAGG CCTGCTCCTCCAGCTGGCTC 
PLS1 GCCAAGACATTAAGGACTCGAGAGC GGATTGCCTGAAACCACATCTGCAG 
LAMA4 GCTCAGGATACTGTGTGCACTGC GGAGCACATCTTTCACAGTTAGGTC 
MMP12 GCATTCAGTCCCTGTATGGAGACC CCAGATGGCAAGGTTGGCCATAAGG 
RHOD GCCTTCCCCGAGAGCTACACC CGACGATGATGGGTACCTTCTTGC 
KRT8 GGCAGCTATATGAAGAGGAGATCCG CAGCCAGGCTCTGCAGCTCC 
ARHGEF5 CCTGAGGGCTCTTCAGATTCAAGAG CGCTGCTGGCTCTGGATCTCC 
COL3A1 GCCTCCAACTGCTCCTACTCGC GGCCAGCTGGTCCAGGATAGC 
COL1A1 GCCAAGACGAAGACATCCCACC GGGTGACTCTGAGCCGTCGG 
LOXL2 GCAAGGGAGAAGGGCCCATCTG CGAATCCGAATGTCCTCCACCTG 
COL1A2 CCTGGTCTCGGTGGGAACTTTGC CCACGAGCACCCTGTGGTCC 
BGN GCACCTCTACGCCCTCGTCC GGTTCCCGCCCATCTCGATGC 
EMILIN1 CGCCACAGGAACTGGTGTGCC GGACTCTCAGCACAGTCATCGC 
MMP2 GGGAGAAGGCCAAGTGGTCCG CCATGGTGAACAGGGCTTCATGG 
RHOJ GGGAACTGACAGCAGCTGCGG GGTTGTAGTCCTCCTGTCCCGC 
LOX GCGACGACCCTTACAACC GGACGCCTGGATGTAGTAGG 
SPARC GGCAGCCCCTCAGCAAGAAGC GGTTCTGGCAGGGATTTTCCGC 
ECM1 CCCAATGAACAGAAGGAAGGAACGC GGAGTAGCTGGACTGTGGTAGG 
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Ewing sarcoma is a unique disease, but the developmental dysregulation so 
prevalent in this malignancy is a commonly used mechanism in tumorigenesis and 
progression. EWS/FLI is a powerful oncogenic transcription factor that interferes with 
many signaling pathways used to direct appropriate cell fate decisions. Of relevance, 
Ewing sarcoma occurs in a very specific age group – adolescents and young adults (Arndt 
& Crist, 1999) - perhaps indicating that the appropriate cell, responsive to the EWS/FLI 
translocation, is not present, is exceedingly rare, or becomes somehow altered in the body 
outside this age range. It seems EWS/FLI requires a very specific cellular context in 
which to target the appropriate genes that lead to transformation. The primitive cell type 
in which this transcriptional mayhem occurs has not been defined. However it surely 
makes significant contributions to oncogenic phenotypes in this tumor.  
One EWS/FLI target gene, BCL11B, was characterized by the work presented 
within showing that its expression contributes to the maintenance of transformation in 
Ewing sarcoma cell lines. BCL11B is normally expressed in the developing CNS (Arlotta 
et al, 2005; Chen et al, 2008), skin (Golonzhka et al, 2009a), teeth (Golonzhka et al, 
2009b) and T-cells (Li et al, 2010). In Ewing sarcoma cells, the expression of BCL11B is 
reduced to undetectable levels in the absence of EWS/FLI. This suggests that BCL11B is 
not normally expressed in the Ewing sarcoma cell of origin. The involvement of BCL11B 
in the development of tissue from several different lineages suggests that its genetic locus 
may be found in a euchromatic region of the genome until a cell differentiates (Gaspar-
Maia et al, 2011). This would provide an accessible promoter region for EWS/FLI to 
induce high level gene expression. We have not tested whether BCL11B is a direct 
transcriptional target of EWS/FLI. However the presence of a variant ETS consensus 
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sequence in the BCL11B promoter region allows for this possibility and warrants future 
investigation.       
BCL11B is a transcription factor and, as demonstrated, transcriptional regulation 
mediated by BCL11B contributes a significant number of genes to the EWS/FLI 
repressed gene signature. Aberrant regulation of other transcription factors and 
transcriptional regulators may be a more general mechanism used by EWS/FLI to 
broaden its transcriptional impact. In a similar way, EWS/FLI up-regulates, the 
homeobox transcriptional repressor, NKX2.2, which then is responsible for a large part of 
the EWS/FLI repressed genes (Owen et al, 2008). At this time several EWS/FLI target 
genes have been shown to contribute to the transformed phenotype. Perhaps the most 
interesting research avenue in this regard is the identification of the minimum set of 
EWS/FLI target genes that need to be expressed or repressed to recapitulate the disease. 
It is unlikely that one or two genes will be sufficient for this task (Kinsey et al, 2006), but 
by including transcriptional regulators, such as BCL11B and NKX2.2, that contribute a 
significant portion of EWS/FLI targets, and genes that disrupt relevant developmental 
signaling pathways, this might be feasible. This could be done in Ewing sarcoma cells 
with EWS/FLI expression reduced by RNAi. In this setting, the loss of transformation 
resulting from EWS/FLI knock-down would be rescued by re-expressing EWS/FLI up-
regulated targets, and reducing the expression of EWS/FLI repressed targets. More 
impressive would be creating a Ewing sarcoma cell from the appropriate precursor cell in 
the absence of EWS/FLI.  
The cell of origin in Ewing sarcoma remains elusive. Several different cell types 
have been proposed – endothelial cells were suggested by James Ewing in 1921 when he 
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first described the disease (Ewing, 1921). Since that time, myelogenous cells (Kadin & 
Bensch, 1971), neural crest cells (Cavazzana et al, 1988), and mesenchymal stem cells 
(Dickman et al, 1982), have all been posited as the cell of origin. One approach to 
identifying this enigmatic cell type is to place less emphasis on EWS/FLI and its target 
genes and more emphasis on genes that are expressed in this cell before the fusion occurs. 
We identified a gene that fit these criteria in our efforts to uncover a factor that could 
collaborate with EWS/FLI in keeping Ewing sarcoma cells in a poorly differentiated 
state. EWS/FLI’s ability to prevent mesenchymal differentiation was well established 
(Tirode et al, 2007; Torchia et al, 2003), so we sought out a gene that could prevent 
epithelial differentiation. The leading candidates were EMT-TF because of their well 
described role in repressing the epithelial phenotype during developmental EMT. The 
two best studied examples of EMT occur during early embryonic development: 
gastrulation where the single epithelial cell layer internalizes to generate mesodermal and 
endodermal cell layers and in neural crest migration where cells of the neural tube 
undergo EMT to gain the migratory capacity necessary to travel throughout the embryo 
(Acloque et al, 2009).  
These efforts led us to ZEB2, an EMT-TF that is highly expressed in Ewing 
sarcoma patient tumors and cell lines, but its expression is not dependent on EWS/FLI 
levels. Genome-wide gene expression analysis confirmed our hypothesis that ZEB2 
repressed epithelial gene expression. In vitro functional assays demonstrated that when 
this ZEB2 enforced epithelial repression was released by reducing ZEB2 levels using 
RNAi, Ewing sarcoma cells adopted more epithelial traits. EMT-TFs contribute to 
metastasis in cancer, in addition to their natural role in development (Thiery et al, 2009), 
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suggesting ZEB2 may facilitate metastasis in Ewing sarcoma. We tested this hypothesis 
and found that the epithelial features in Ewing sarcoma cells realized upon reduction of 
ZEB2, led to a decreased metastatic potential of these cells in an orthotopic mouse 
metastasis model. These findings have promise in translating to the realm of patient care.  
Metastatic disease is indicative of a very poor prognosis in Ewing sarcoma 
patients. Current therapy which includes aggressive chemotherapy, radiation and surgery 
achieves cure rates of 70% for patients with localized disease (McAllister & Lessnick, 
2005). At this time, there is no effective therapy for patients with disseminated disease. In 
one large prospective clinical trial, patients with metastatic disease had a five-year overall 
survival just over 30% compared to over 70% for those with localized disease treated on 
the same protocols (Grier et al, 2003). ZEB2 may have potential to serve as a prognostic 
indicator. Patients with tumors expressing low levels of ZEB2 may have less chance for 
metastasis owing to the more epithelial nature of their tumor. ZEB2 expression in 
combination with other epithelial markers may predict which patients presenting with 
localized disease are most likely to have micrometastatic disease. Patients could then be 
stratified according to their risk and treated accordingly, thus limiting the toxic and long 
lasting effect of chemotherapy and radiation on these children and young adults.  
The cellular plasticity that has been demonstrated in Ewing sarcoma may have 
therapeutic potential. Studies in carcinoma have suggested that epithelial characteristics 
of cancer cells endow them with a proliferative capacity at primary and secondary sites, 
while mesnchymal features are required to escape the primary tumor, survive in the blood 
stream, and arrive at the secondary site. These studies have led to some speculation about 
opportunity for differentiation therapy. A much better understanding of this cellular 
93 
plasticity and how tumor cells call upon aspects of these two cell types at certain stages 
of disease is needed before treatments are based upon the idea. Keeping this in mind, it is 
worth thinking about for the future. In Ewing sarcoma, if one could be truly certain a 
tumor had not disseminated, a treatment that could elicit epithelial characteristics, similar 
to the effects achieved by knocking-down ZEB2, might be beneficial. This may limit or 
prevent the tumor’s metastatic potential. Due to the reality that metastasis is an early 
event in Ewing sarcoma, and in most cases the disease has already spread at the time of 
presentation, therapy nudging tumors toward the mesenchymal lineage may be a better 
approach. In this way, the cancer cells would lose proliferative capacity keeping the 
primary tumor from progressing and inhibiting outgrowth of micrometastases. This 
concept is supported by the observation that many Ewing sarcoma cell lines proliferate 
more slowly, or not at all, when EWS/FLI expression is reduced. While loss of EWS/FLI 
has many consequences, one that could contribute to this reduced growth is the shift 
toward the mesenchymal phenotype.  
The importance of ZEB2 in Ewing sarcoma pathogenesis combined with a greater 
appreciation of the epithelial plasticity provides new insight into the cell of origin for this 
disease. Identifying a precursor cell has been a major challenge in the field and has 
severely limited study of disease development and progression and prevented the use of 
relevant animal models. The epithelial plasticity of Ewing sarcoma cells had not been 
experimentally demonstrated prior to this work. This finding warrants questioning of the 
generally accepted MSC cell of origin hypothesis. We prefer a model that integrates the 
long held belief that Ewing sarcoma originated from neural crest with the more recently 
favored MSC model. We propose that the cell of origin is an intermediate between neural 
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crest and an MSC. Two independent labs have demonstrated that neural crest can give 
rise to MSCs, and this is true for both mouse and human cells (Lee et al, 2007; 
Takashima et al, 2007).  
Experimental investigation of ZEB2 in early embryonic development lends 
support for this model. Zeb2 is expressed in the neural crest and neuroepithelium during 
mouse embryogenesis and is required for neural crest migration. Homozygous Zeb2 
knock-out mice die on embryonic day 8.5 due to neural crest migration defects. This 
highlights the role of ZEB2 in facilitating a developmental EMT in neural crest cells. By 
extension, ZEB2 expression in the human neural crest may induce EMT and during this 
transition the EWS/FLI translocation occurs, thus preventing the mesenchymal 
destination. This results in a poorly differentiated Ewing sarcoma cell that is “stuck” 
between epithelial and mesenchymal lineages, but has access to features of both cell 
types.  
This alternative take on the cell of origin provides a new avenue for investigation 
in developing a mouse model for Ewing sarcoma. So far efforts to genetically engineer 
EWS/FLI expression in various mouse cell types have been fruitless. EWS/FLI 
expression in hematopoetic precursors gives rise to leukemias and lymphomas 
(Codrington et al, 2005; Torchia et al, 2007) and expression of the translocation in 
mesoderm derived limb bud did not induce tumor formation (Lin et al, 2008). In light of 
the hypothesis presented here, one might try to model this cancer in a neural crest cell 
undergoing EMT. To target this transitioning cell, EWS/FLI expression could be placed 
under dual control of a neural crest or neuroepithelium marker such as Sox1 in addition to 
Zeb2, ensuring expression in a population of cells undergoing EMT. This work could be 
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complemented with in vitro modeling, which could be achieved by expressing EWS/FLI 
at various times following the culture systems described to generate MSCs via neural 
crest stem cells (Lee et al, 2007; Takashima et al, 2007). One advantage of the in vitro 
system is the use of human cells which notably have different requirements for 
transformation as compared to mouse cells (Rangarajan et al, 2004). This system could 
be further enhanced by using the newly described zinc finger and TALE nuclease 
technology to engineer targeted double strand breaks that result in the generation of 
translocations in the appropriate genomic context (Piganeau et al, 2013). In this way, 
heterozygousity and potential haploinsufficiency resulting from the translocation are 
accomplished.  
A more comprehensive understanding of the contributions made by EWS/FLI and 
the appropriate cellular context in Ewing sarcomagenesis will provide useful knowledge 
about the disease that will translate to improved patient care. Identification of the cell of 
origin to enable modeling of the disease both in mice and human cells is a necessary 
intermediate in achieving this goal. Critical steps in tumor development including 
information regarding the time from the translocation event to initiation of transformation 
as well as disease penetrance can be elucidated. Mouse models will allow for study of the 
natural disease progression including monitoring metastasis in real time. Contributions of 
EWS/FLI target genes can also be better assessed using knock-ins and knock-outs of 
genes of interest rather than ectopic expression or RNAi-mediated approaches where the 
desired effect (ie gene knock-down) is often lost over the course of the study.  These 
animals will also provide a relevant system in which to test new cancer therapies 
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including agents to target specific developmental pathways, differentiation therapy, and 
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